Sunday, July 6, 2025 7/6/2025

Targeting stroke-induced brain swelling in obese subjects: role of VEGF

Award Number: R01NS103326
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/15/2018
PERIOD OF PERFORMANCE END DATE: 12/31/2023

Group Awards By:

View Award Description

Targeting stroke-induced brain swelling in obese subjects: role of VEGF - Project Summary Stroke is the leading cause of physical disability worldwide and represents a global socioeconomic burden to human health. Despite an intense research effort that led to a plethora of targets and neuroprotectants to reduce stroke-induced brain injury in animals, the neuroprotection-based strategies resulted in little or no efficacy in numerous controlled clinical trials. These observations indicate that there should be a paradigm shift to enhance the translational efficacy issue and improve this devastating condition. Potential missing links that account for the translational hindrances include solely relying on infarct size without considering brain swelling to gauge neuroprotection in preclinical studies. In addition, there is a paucity of inclusion of risk factors in animal models of stroke, whereas comorbidities such as dyslipidemia, hypertension, diabetes, and obesity are frequently observed conditions in patients. The combined evidence supports the conclusion that there is a critical need to define stroke pathology focusing on brain swelling in metabolically compromised conditions, which is the overall scientific premise for the proposed research. Our recent findings showed that mice with diabetes and hyperlipidemia displayed disproportionately larger brain swelling compared to infarct volume, and the enhanced brain swelling was closely associated with an increased level of vascular endothelial growth factor receptor 2 (VEGFR2), a key signaling molecule for vascular permeability and angiogenesis. As obesity is a precipitating cause leading to metabolic disorders including diabetes and dyslipidemia, we hypothesized that VEGFR2 underlies obesity-enhanced brain swelling in stroke and that blocking VEGFR2 activation reduces the swelling and promotes functional recovery in obesity. Aim 1 will identify the role of VEGFR2 activation(s) on stroke-induced brain swelling in obese mice by assessing histological and molecular outcomes. In Aim 2, the loss and gain of function studies will evaluate the efficacy of VEGFR2 modulation on obesity-enhanced stroke-induced brain swelling using pharmacological and genetic approaches. Aim 3 will determine the impact of brain swelling on long-term stroke recovery by assessing long-term motor and cognitive function in obese mice where VEGF signaling is manipulated. At the completion of the project, we expect to obtain scientific evidence establishing the importance of VEGF signaling in obesity-enhanced brain swelling, the utility of VEGF inhibition as a treatment strategy in obesity stroke, and reducing brain swelling as an approach to promoting long-term stroke recovery. These results are expected to have a significant impact by providing strong justification for the repurposing of available VEGF-targeted anti- angiogenic/anti-cancer drugs to treat stroke patients with obesity and its associated comorbidities.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = $0 )
2024	2022	THE WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	6/17/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $404,688 )
2022	2022	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	11/26/2021	NON-COMPETING CONTINUATION	$364,219
2022	2022	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	3/31/2022	NON-COMPETING CONTINUATION	$40,469
														Subtotal = $404,688

Issue Date FY: 2021 ( Subtotal = $404,688 )
2021	2021	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	12/22/2020	NON-COMPETING CONTINUATION	$364,219
2021	2021	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	4	1/11/2021	NON-COMPETING CONTINUATION	$40,469
														Subtotal = $404,688

Issue Date FY: 2020 ( Subtotal = $404,688 )
2020	2020	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	12/31/2019	NON-COMPETING CONTINUATION	$364,219
2020	2020	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	3	8/13/2020	NON-COMPETING CONTINUATION	$0
2020	2020	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	2/11/2020	NON-COMPETING CONTINUATION	$40,469
														Subtotal = $404,688

Issue Date FY: 2019 ( Subtotal = $404,688 )
2019	2019	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	12/13/2018	NON-COMPETING CONTINUATION	$404,688
														Subtotal = $404,688

Issue Date FY: 2018 ( Subtotal = $404,688 )
2018	2018	WINIFRED MASTERSON BURKE MEDICAL RESEARCH INSTITUTE, INC, THE	785 MAMARONECK AVE	WHITE PLAINS	NY	10605	WESTCHESTER	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	2/5/2018	NEW	$404,688
														Subtotal = $404,688

Grand Total All Awards = $2,023,440

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Targeting stroke-induced brain swelling in obese subjects: role of VEGF

Award Number: R01NS103326

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/15/2018

PERIOD OF PERFORMANCE END DATE: 12/31/2023

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer